CymaBay Therapeutics to Present at Upcoming Investor Conferences
10 févr. 2022 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
18 nov. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative...
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
17 nov. 2021 16h33 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative...
CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC
15 nov. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
Study results presented at The Liver Meeting® 2021 demonstrated continued reductions in biomarkers of cholestasis and hepatocellular injury over two yearsSeladelpar generally appeared safe with low...
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
11 nov. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
10 nov. 2021 16h06 HE
|
CymaBay Therapeutics, Inc.
Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC) Additional data from prior studies of seladelpar in...
CymaBay Therapeutics to Present at Upcoming Investor Conferences
04 nov. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
03 nov. 2021 16h05 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021
01 oct. 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Therapeutics to Present at Upcoming Investor Conferences
30 août 2021 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...